Myron Levin, MD
Professor, Pediatrics-Infectious Diseases

Photo
Medical School:
  • MD, Harvard Medical School (1964)
Undergraduate School:
  • BA, Harvard University (MA) (1960)
Internship:
  • Albert Einstein College of Medicine (Jacobi) Program (1965)
Residency:
  • Albert Einstein College of Medicine (Jacobi) Program, Internal Medicine (1966)
Fellowships:
  • Beth Israel Deaconess Medical Center Program, Infectious Disease (1971)
Languages: English
Department: Pediatrics-Infectious Diseases

Professional Titles

  • Associate Director, Pediatric HIV Clinic

Research Interests

Dr. Levin is studying the immune response to herpes virus infections and methods of treating and preventing such infections, including antiviral therapy and active immunization. He does basic research on the nature of latency of herpes viruses in human neurons. A vaccine to prevent shingles in elderly individuals has been developed and licensed through his clinical research, and further investigations of this vaccine are in progress.

Publications

  • Weinberg A, Schmid DS, Leung J, Johnson MJ, Miao C, Levin MJ. Predictors of five-year persistence of antibody responses to zoster vaccines. J Infect Dis 2023;228:1367-1374.
  • Tuffy KM, Ahani B, Aksyuk AA, Avila M, Brady T, Kijak GH, Koh G, Levin MJ, Roe TL, Schuko N, Ustianowski A, Zhang T, Kelly EJ, and Streicher K. Analysis of SARS-CoV-2 variants identified from breakthrough infections in the PROVENT prevention trial of AZD7442 (Tixagevimab/Cilgavimab) J Infect Dis 2023; 228: 1055-1059.
  • Janoff EN, Tseng H-F, Nguyen JL, Alfred T, Vietri J, McDaniel A, Chilson E, Yan Q, Malhotra D, Isturiz RE, Levin MJ. Incidence and Clinical Outcomes of Pneumonia in Persons with Down Syndrome in the United States. Vaccine 2023; 41: 4571-4578.
  • Laing KJ, Ford ES, Johnson MJ, Levin MJ, Koelle DM, Weinberg A. Recruitment of naïve CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest 2023; e172634; PMID: 37788096
  • Albrecht M, Levin MJ. Treatment of herpes zoster in the immunocompetent host. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised and accessed September 27, 2023.
  • Albrecht M, Levin MJ. Treatment of herpes zoster in the immunocompetent host. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised and accessed July 27, 2022.
  • Bunik M, Hay WH, Levin MJ, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 26th Ed. Lange Medical Books-McGraw–Hill Companies (New York); 2022.
  • Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, and Parikh SA. Humoral and cellular immune responses to the recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia or monoclonal B cell lymphocytosis. Am J Hematol 2022; 97: 90-98,. doi:10.1002/ajh.2638
  • Johnson MJ, Liu C, Debashis G, Lang N, Levin MJ, Weinberg A. Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: Five-year persistence. J Infect Dis 2022,225: 1477-1481.
  • J. Divino V, Anupindi R, DeKoven M, Mould-Quevedo J, Pelton SI, Postma MJ, Levin MJ. A Real-World Clinical and Economic Analysis of Cell-derived Quadrivalent Influenza Vaccine Compared to Standard Egg-derived Quadrivalent Influenza Vaccines During the 2019-20 Influenza Season in the United States. Open forum Infectious Diseases, 2022; https://doi.org/10.1093/ofid/ofab604
  • Levin M, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near A, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT on behalf of the PROVENT Study Group. Intramuscular AZD7442 (tixagevimab/cilgavimab) for prevention of COVID-19. NEJM 2022; 386: 2188.
  • Ku JH, Levin MJ, Luo Y, Florea A, Lin I-C, Tian Y, Tseng H-F. Risk of severe COVID-19 infection in individuals with Down syndrome: a matched-cohort study from a large, integrated healthcare system. Clin Infect Dis 2022; 226; 757-765.
  • Schmader KS, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Herve C, Grupping K, Schuind AE, Oostvogels L, Curran D. Impact of reactogenicity after two doses of recombinant zoster vaccine upon physical functioning and quality of life: an open phase III trial in older adults. J Gerontology A Biol Sci Med Sci 2021: 76: 485-490
  • Curran D, Hyung Kim J, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, McNeil SA, Schuind AE, Andrew MK. Recombinant Zoster Vaccine is efficacious and safe in frail individuals. J Am Geriatrc Soc 2021; 69: 744-752.
  • Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. Brit Med J 2021; 372: n188; http://dx.doi/org/10.1136/bmj.n188.
  • Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, and Levin MJ. Comparison antibody responses to the live-attenuated and recombinant herpes zoster vaccines. J Virology 2021; 95: e00240-21.
  • Callegaro A, Burny W, Hervé C, Kim JH, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine J Infect Dis 2021).
  • Anupindi VR, DeKoven M, Divino V, Pelton SI, Levin MJ, Mould-Quevedo J, Postma MJ. A Real-World Clinical and Economic Analysis of Cell-derived Quadrivalent Influenza Vaccine Compared to Standard Egg-derived Quadrivalent Influenza Vaccines During the 2019-20 Influenza Season in the United States (Accepted Vaccine, 2021).
  • Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, and Parikh SA. Humoral and cellular immune responses to the recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia or monoclonal B cell lymphocytosis. Am J Hematology.
  • Johnson MJ, Liu C, Debashis G, Lang N, Levin MJ, Weinberg A. Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: Five-year persistence. (Accepted, J Infect Dis, 2021).
  • Divino V, Anupindi R, DeKoven M, Mould-Quevedo J, Pelton SI, Postma MJ, Levin MJ. A Real-World Clinical and Economic Analysis of Cell-derived Quadrivalent Influenza Vaccine Compared to Standard Egg-derived Quadrivalent Influenza Vaccines During the 2019-20 Influenza Season in the United States. (Accepted Open Forum Infectious Diseases, 2021).
  • Albrecht M, Levin MJ. Treatment of herpes zoster in the immunocompetent host. Post TW, ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Accessed July 7, 2021.
  • Duchon JM, Levin, MJ, Gershon AA. Safety and varicella outcomes in in utero-exposed newborns and preterm infants treated with varicella zoster immune globulin (VARIZIG): A subgroup analysis of an expanded access program. J pediatric infectious diseases society 2020; 9: 449-453.
  • Levin MJ, Weinberg A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin Infect Dis 2020; 70: 1509-1515. PMID: 31618437.
  • Kim J, Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Levin M, Oostvogels L, Zahaf T, Schuind A and Cunningham A on behalf of the ZOE-50/70 study group. Post-hoc analysis of reactogenicity trends between Dose 1 and Dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Human vaccines and immunotherapeutics, 2020: 10.1080/21645515.2020.1741312.
  • Curran D, Hyung Kim J, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, McNeil SA, Schuind AE, Andrew MK. Recombinant Zoster Vaccine is efficacious and safe in frail individuals. J Am Geriatrc Soc, Nov 16, 2020). https://doi.org/10.1111/jgs.16917.
  • Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed. Lange Medical Books-McGraw–Hill Companies (New York), 2020
  • Gaensbauer J, Levin MJ: Chap 43. Infections: Parasitic and Mycotic. In: Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed., Lange Medical Books-McGraw Hill (New York). 2020, pg 1236-1299.
  • 0lson D. Asturias EJ, Levin MJ: Infections: Chap. 40. Infections: Viral and Ricketsial In: Hay WW, Levin MJ, Bunik,M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed., Lange Medical Books-McGraw Hill (New York) 2020, pg 1178-1224.
  • Albrecht MA, Levin MJ. Post-exposure prophylaxis against varicella-zoster virus infection. Post TW ed. UpToDate Inc, Waltham, MA. http://www.uptodate.com. Revised 2/3/20.
  • Levin MJ. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. AIDSinfo https://aidsinfo.nih.gov/guidelines/html/5/pediatric-opportunistic-infection/419/varicella-zoster-virus.
  • Johnson RW, Levin MJ. Herpes zoster and its prevention by vaccination. In: Weinberger B (ed): Current Vaccines for the Older Population: Current Practices and Future Opportunities. Interdiscip Topics Gerontol Geriatr. Basel, Karger, 2020; 43: 131-145 (DOI: 10.1159/000504484).
  • Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM, Bwakura-Dangarembizi M, Ogwu A, Mpabalwani EM, Sato P, Siberry G, Nelson M, Hille D, Weinberg GA, Weinberg A. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS. 2017 Jan 2;31(1):49-59. PubMed PMID: 27662551
  • Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. J Infect Dis. 2016 Jan 1;213(1):14-22. PubMed PMID: 26452397
  • Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Aug;16(8):915-22. PubMed PMID: 27061887
  • Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. PubMed PMID: 27626517
  • Lee E, Cho HJ, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep. 2013 Nov 1;36(11):1685-91. PubMed PMID: 24179302
  • Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine. 2013 Oct 1;31(42):4782-90. PubMed PMID: 23954381
  • Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 1;208(9):1386-90. PubMed PMID: 23908486
  • Lee KS, Zhou W, Scott-McKean JJ, Emmerling KL, Cai GY, Krah DL, Costa AC, Freed CR, Levin MJ. Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One. 2012;7(12):e53010. PubMed PMID: 23285249
  • Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines. 2012 Nov;11(11):1293-303. PubMed PMID: 23151111
  • Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A on behalf of the ZOE-50/70 study group. Efficacy and serious adverse event profile of the adjuvanted recombinant zoster in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology
  • Schmader KS, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Herve C, Grupping K, Schuind AE, Oostvogels L, Curran D. Impact of reactogenicity after two doses of recombinant zoster vaccine upon physical functioning and quality of life: an open phase III trial in older adults (in press, J Gerontology: Medical Sciences, 2020).
  • Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, and Levin MJ. Comparison antibody responses to the live-attenuated and recombinant herpes zoster vaccines (in press, J Virology, 2020)
  • Cunningham AC, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for the ageing. Brit Med J
  • Park SY, Levin MJ, Canniff J, Johnson M, Weinberg A. Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. (Clin Infect Dis, in press 2022).
  • Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; on behalf of the STORM CHASER Study Group. AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19. (Clin Infect Dis, accepted 2022)
  • .Levin MJ. Chapter 6 Zoster Vaccines. In: Plotkin S, Orenstein W, Offitt P, Edwards KM (Eds): Vaccines. 8h Edition, Elsevier (USA). 2022:
  • Hay WW, Levin MJ, Bunik M, Abzug MJ (eds): Current Pediatric Diagnosis & Treatment, 25th Ed. Lange Medical Books-McGraw–Hill Companies (New York), (in press);
  • DeKoven M, Divino V, Levin MJ, Mould-Quevedo J, Pelton SI, Postma MJ, Zhou Z. A Clinical and Economic Assessment of Adjuvanted Trivalent Versus Standard Egg-Derived Quadrivalent Influenza Vaccines Among Older Adults in the United States During the 2018-19 and 2019-20 Influenza Seasons (in press)
  • Bunik M, Levin MJ, Abzug MJ. Schreier T (eds): Current Pediatric Diagnosis & Treatment, 27th Ed., Lange Medical Books-McGraw Hill (New York) 2023 (in press).
View All (51 Total) View Less

Professional Memberships

  • Infectious Diseases Society of America, Fellow
  • Pediatric Infectious Disease Society, Fellow

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado
  • University of Colorado Hospital

Specialty Information

Specialties
  • Internal Medicine, Board Certification (1979)
  • Infectious Disease, Board Certification (1996)
Conditions & Treatments
  • Infections - Viral Infections
  • Infections - Sexually Transmitted Diseases
  • Immune System - AIDS
  • Immune System - AIDS / HIV Disease
  • Immune System
  • Infections
Clinical Interests
I am interested in Clinical Virology, Antiviral Therapy and Herpes Virus Infections.

General Information

Medical Schools:
  • MD, Harvard Medical School (1964)
Undergraduate Schools:
  • BA, Harvard University (MA) (1960)
Internships:
  • Albert Einstein College of Medicine (Jacobi) Program (1965)
Residency Programs:
  • Albert Einstein College of Medicine (Jacobi) Program, Internal Medicine (1966)
Fellowships:
  • Beth Israel Deaconess Medical Center Program, Infectious Disease (1971)
Languages: English
Department: Pediatrics-Infectious Diseases
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;